| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702612 | Urologic Oncology: Seminars and Original Investigations | 2017 | 10 Pages |
Abstract
Cytoreductive prostatectomy in mPCa is a feasible procedure that may improve outcomes for men when combined with multimodal management. Preclinical, translational, and retrospective evidence supports local therapy for metastatic disease. However, currently, evidence is limited and is subject to bias. The results of ongoing prospective randomized trials are required before incorporating this therapeutic strategy into clinical practice.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Michael J. M.D., Marc C. M.D., M.S.H.P., Daniel W. M.D., Ana M. M.D., Brian F. M.D.,